Fumaric Acid

For the treatment of relapsing forms of multiple sclerosis, the dosing of dimethyl fumarate (e.g., Tecfidera) typically follows a strict titration schedule to improve gastrointestinal tolerability:

• Starting Dose: 120 mg taken orally twice daily for the first 7 days.
• Maintenance Dose: After the initial 7 days, the dose is increased to the standard maintenance level of 240 mg taken orally twice daily.

For diroximel fumarate (Vumerity), the schedule is similar:

• Starting Dose: 231 mg twice daily for 7 days.
• Maintenance Dose: 462 mg (two 231 mg capsules) twice daily.

In the treatment of psoriasis with FAEs (e.g., Skilarence), the titration is often much slower, starting at 30 mg daily and increasing weekly by 30 mg increments until a clinical response is achieved or a maximum dose of 720 mg per day is reached.

The safety and effectiveness of fumaric acid derivatives in pediatric patients (under 18 years of age) have not been fully established by the FDA. While some clinical trials have explored the use of dimethyl fumarate in children with MS, it is not currently a standard approved indication. Healthcare providers may occasionally prescribe it off-label for adolescents, but this requires specialized pediatric neurology oversight.

Renal Impairment

Clinical studies suggest that no dosage adjustment is necessary for patients with mild, moderate, or severe renal impairment. However, because a small portion of the drug is excreted renally, clinicians should exercise caution in patients with end-stage renal disease (ESRD).

Hepatic Impairment

No dosage adjustment is typically required for patients with hepatic impairment. However, because fumaric acid can rarely cause elevations in liver enzymes, patients with pre-existing liver disease should be monitored closely with regular Liver Function Tests (LFTs).

Elderly Patients

Clinical trials did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.

To ensure the best results and minimize side effects, patients should follow these guidelines:

• Consistency: Take the medication at the same time every day, ideally about 12 hours apart.
• With Food: Taking fumaric acid with food (especially a meal containing fat and protein) significantly reduces the incidence and severity of skin flushing and gastrointestinal upset.
• Swallow Whole: Capsules or tablets must be swallowed whole. Do not crush, chew, or sprinkle the contents on food, as this can destroy the delayed-release coating and increase the risk of stomach irritation.
• Storage: Store the medication at room temperature (68°F to 77°F) in its original light-resistant container. Keep the bottle tightly closed and protect it from moisture.

If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one. Frequent missed doses can reduce the effectiveness of the treatment in preventing MS relapses.

In the event of an overdose, patients may experience intensified side effects, particularly severe gastrointestinal distress (vomiting, diarrhea) and extensive skin flushing.

• Emergency Measures: If an overdose is suspected, contact your local Poison Control Center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on hydration and management of gastrointestinal symptoms. There is no specific antidote for fumaric acid poisoning.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a return of disease symptoms.

Fumaric acid derivatives are associated with several common side effects, particularly during the first few weeks of treatment. These are often manageable and tend to diminish over time as the body adjusts to the medication.

• Flushing: This is the most frequently reported side effect, occurring in up to 40% of patients. It involves a feeling of warmth, redness, itching, or a burning sensation, usually on the face, neck, or upper body. It typically starts within 1-3 hours of taking a dose.
• Gastrointestinal Distress: Diarrhea, nausea, and abdominal pain are very common. These symptoms are often the primary reason patients discontinue therapy. Taking the medication with food can significantly alleviate these issues.
• Upper Abdominal Pain: Often described as a "gnawing" or cramping sensation in the stomach area.
• Vomiting: Less common than nausea but still a significant issue during the titration phase.

• Proteinuria: The presence of excess protein in the urine, which may indicate temporary changes in kidney filtration.
• Erythema: Generalized skin redness beyond the typical flushing response.
• Dyspepsia: Indigestion or heartburn.
• Pruritus: General body itching without a visible rash.
• Lymphocytopenia: A decrease in the number of lymphocytes (a type of white blood cell). While common, it is usually mild, but severe cases require medical intervention.

• Eosinophilia: An increase in eosinophils (white blood cells involved in allergic reactions).
• Liver Enzyme Elevation: Increases in ALT or AST levels, which may indicate liver stress.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.

> Warning: Stop taking Fumaric Acid and call your doctor immediately if you experience any of these serious symptoms.

• Progressive Multifocal Leukoencephalopathy (PML): This is a rare but potentially fatal brain infection caused by the JC virus. Symptoms include new or worsening weakness on one side of the body, clumsiness, vision changes, confusion, or personality changes. It usually occurs in patients with prolonged low lymphocyte counts.
• Severe Allergic Reactions (Anaphylaxis): Symptoms include difficulty breathing, swelling of the throat or tongue, and hives.
• Clinically Significant Liver Injury: Signs include yellowing of the skin or eyes (jaundice), dark urine, and severe right-sided abdominal pain. Reports of liver injury have occurred as early as a few weeks after starting treatment.
• Opportunistic Infections: Due to the immunomodulatory nature of the drug, patients may be at higher risk for serious viral (e.g., Herpes Zoster), bacterial, or fungal infections.
• Severe Lymphocytopenia: If the Absolute Lymphocyte Count (ALC) falls below 500 cells/mm³ for an extended period, the risk of infection increases dramatically.

• Immune System Changes: Long-term use of fumaric acid can lead to a sustained reduction in white blood cell counts, requiring lifelong monitoring to prevent infections.
• Gastrointestinal Sensitivity: Some patients may develop chronic low-grade GI sensitivity, necessitating permanent dietary adjustments or the use of adjunctive medications like bismuth subsalicylate.
• Bone Health: While data is limited, some studies suggest that chronic immunomodulation may affect bone turnover markers, though clinical impact remains under investigation.

As of 2024, the FDA has not issued a formal Black Box Warning for dimethyl fumarate or diroximel fumarate. However, the labels contain "Warnings and Precautions" regarding PML, lymphocytopenia, and liver injury that are considered critical for prescriber and patient awareness. In some jurisdictions, the risk of PML is highlighted with similar gravity to a boxed warning.

Report any unusual symptoms to your healthcare provider. Early detection of side effects is key to maintaining a safe treatment regimen.

Fumaric acid derivatives are powerful immunomodulators that require careful medical supervision. Before starting treatment, patients must undergo a baseline blood test, including a complete blood count (CBC) and liver function tests. These tests must be repeated regularly (typically every 3 to 6 months) to ensure the medication is not causing hidden damage to the immune system or liver.

No FDA black box warnings for Fumaric Acid. However, the FDA has issued several safety communications regarding the risk of Progressive Multifocal Leukoencephalopathy (PML) associated with fumaric acid esters. Clinicians are advised to monitor lymphocyte counts rigorously and discontinue the drug if severe lymphocytopenia persists.

• Allergic Reactions / Anaphylaxis Risk: Patients may develop hypersensitivity to fumaric acid or any of the inactive ingredients (such as microcrystalline cellulose or croscarmellose sodium). Symptoms of anaphylaxis require emergency intervention and permanent discontinuation of the drug.
• Infection Risk: Because fumaric acid reduces certain white blood cell counts, it can lower your ability to fight infections. Patients should be screened for tuberculosis (TB) and other chronic infections before starting therapy. If a serious infection develops, the drug should be withheld until the infection resolves.
• Hepatotoxicity: There have been post-marketing reports of clinically significant liver injury. Patients should be monitored for signs of liver dysfunction, and the drug should be stopped if liver enzymes exceed 3 times the upper limit of normal.
• PML Risk: PML is an opportunistic viral infection of the brain that can lead to severe disability or death. The risk is higher in patients who have been on the drug for more than 2 years or those with a history of immunosuppressant use.
• Gastrointestinal Disease: Use with caution in patients with active severe gastrointestinal disease, such as Crohn's disease or ulcerative colitis, as the drug may exacerbate symptoms.

• Complete Blood Count (CBC): Required before starting, at 6 months, and then every 6-12 months thereafter. If the lymphocyte count falls below 0.5 x 10^9/L for more than six months, the drug should be discontinued.
• Liver Function Tests (ALT, AST, Bilirubin): Required before starting and as clinically indicated during treatment.
• MRI Monitoring: In patients at high risk for PML, periodic MRI scans may be used to detect early lesions before clinical symptoms appear.

Fumaric acid is not known to have a significant effect on the ability to drive or operate machinery. However, if a patient experiences significant flushing or GI distress that causes distraction or discomfort, they should wait until symptoms subside before engaging in these activities.

Alcohol consumption should be limited while taking delayed-release fumaric acid. High concentrations of alcohol can cause "dose-dumping," where the delayed-release coating of the capsule dissolves too quickly in the stomach, leading to a rapid release of the medication. This significantly increases the risk of severe gastrointestinal side effects and may alter the drug's effectiveness.

There is no evidence of a withdrawal syndrome or "rebound effect" when stopping fumaric acid. However, MS symptoms may eventually return to their pre-treatment baseline. Patients should never stop the medication without consulting their neurologist, as a transition plan to another disease-modifying therapy may be necessary.

> Important: Discuss all your medical conditions, including any history of low white blood cell counts, liver disease, or kidney disease, with your healthcare provider before starting Fumaric Acid.

Fumaric acid should not be used in combination with other fumaric acid esters (e.g., taking both Tecfidera and Fumaderm). This leads to an excessive dose and a high risk of severe toxicity, particularly profound lymphocytopenia and renal damage.

• Immunosuppressants and Antineoplastics: Drugs such as methotrexate, cyclophosphamide, or azathioprine can have additive effects on the immune system when taken with fumaric acid. This significantly increases the risk of opportunistic infections and PML. If switching from a potent immunosuppressant to fumaric acid, a "washout period" is often required.
• Nephrotoxic Agents: While fumaric acid is generally not toxic to the kidneys at standard doses, combining it with other drugs that can damage the kidneys (like aminoglycoside antibiotics, lithium, or high-dose NSAIDs) may increase the risk of renal impairment.

• Corticosteroids: Short-term use of steroids for MS relapses is generally considered safe, but long-term combination may further suppress the immune system.
• Live Vaccines: The use of live attenuated vaccines (e.g., MMR, Varicella, Yellow Fever) should be avoided during treatment. The immune response to the vaccine may be diminished, or the vaccine virus may cause an actual infection due to the patient's altered immune state.

• High-Fat Meals: A high-fat, high-calorie meal can delay the absorption of fumaric acid, which is actually beneficial. Clinical trials have shown that taking the medication with a meal containing approximately 30g of fat significantly reduces the incidence of skin flushing.
• Dairy Products: Some patients find that taking the medication with yogurt or milk helps coat the stomach and reduce the "burning" sensation associated with the medication.

• St. John's Wort: While fumaric acid is not metabolized by the CYP3A4 system, St. John's Wort can affect overall immune function and should be discussed with a doctor.
• Antioxidant Supplements: High doses of other Nrf2 activators or antioxidants (like sulforaphane or curcumin) might theoretically have additive effects, though the clinical significance is unknown.

• Urinary Ketones: Fumaric acid may cause false-positive results for ketones in some urine dipstick tests. If you are a diabetic monitoring for ketoacidosis, inform your doctor that you are taking this medication.
• Liver Enzymes: As mentioned, the drug can cause elevations in ALT and AST, which may be misinterpreted if the clinician is unaware of the medication use.

Management Strategy

For most interactions, the management strategy involves:

1. 1Baseline Testing: Establishing a clear picture of blood and organ function before starting.
2. 2Dose Timing: Separating the dose of fumaric acid from other medications that cause GI upset.
3. 3Regular Monitoring: Increasing the frequency of blood tests when adding new medications.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and share it with every healthcare provider you visit.

Fumaric acid and its derivatives must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients who have had a severe allergic reaction (anaphylaxis or angioedema) to dimethyl fumarate, diroximel fumarate, or any component of the formulation. The mechanism is an IgE-mediated or delayed hypersensitivity response that can be life-threatening.
• Co-administration with other FAEs: Using multiple fumarate products simultaneously is contraindicated due to the risk of acute overdose and severe leucopenia.

In these cases, the healthcare provider must perform a careful risk-benefit analysis:

• Pre-existing Severe Lymphocytopenia: If a patient's baseline lymphocyte count is below 0.5 x 10^9/L, starting fumaric acid is generally avoided as it will likely drop the levels further into a dangerous range.
• Active Severe Infection: Treatment should not be initiated in patients with serious active infections (e.g., active TB, systemic fungal infections) until the infection is fully resolved.
• Severe Gastrointestinal Disease: Patients with active peptic ulcer disease or severe inflammatory bowel disease may find the GI side effects of fumaric acid intolerable.
• Severe Renal or Hepatic Disease: While not an absolute contraindication, the lack of extensive data in these populations requires extreme caution.

Patients who are sensitive to other dicarboxylic acids or organic acid esters should be monitored closely. There is a potential for cross-reactivity between different fumaric acid esters (e.g., if a patient reacted to a psoriasis treatment containing fumarates, they should not be given the MS version).

> Important: Your healthcare provider will evaluate your complete medical history, including any history of shingles, low white blood cell counts, or stomach problems, before prescribing Fumaric Acid.

Fumaric acid derivatives are generally not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus.

• FDA Category: Previously classified as Category C. Animal studies have shown evidence of embryofetal toxicity, including reduced fetal body weight and skeletal variations at doses that were also toxic to the mothers.
• Clinical Recommendation: Women of childbearing age should use effective contraception during treatment. If a patient becomes pregnant while taking fumaric acid, they should contact their neurologist immediately to discuss the risks of continuing versus the risk of an MS relapse during pregnancy.

It is not known whether fumaric acid or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (such as GI distress or immune suppression), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

As of 2024, the safety and efficacy of fumaric acid in patients under the age of 18 have not been established. Clinical trials in pediatric MS are ongoing. Use in this population is considered off-label and must be managed by a specialist in pediatric neurology or dermatology.

Clinical studies of dimethyl fumarate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are more likely to have decreased renal or hepatic function and are often on multiple medications (polypharmacy). This increases the risk of drug interactions and side effects. Close monitoring of blood pressure and renal function is recommended in this age group.

In patients with renal impairment, the pharmacokinetics of monomethyl fumarate are not significantly altered. No dose adjustment is required for mild to severe impairment. However, since the long-term effects on renal tubules are not fully documented in humans, periodic urinalysis may be prudent in patients with pre-existing kidney disease.

Fumaric acid does not undergo hepatic metabolism via the CYP450 system, so liver impairment does not significantly affect the clearance of the drug. However, because the drug itself can cause liver injury, patients with Child-Pugh Class B or C hepatic impairment should be monitored with more frequent liver function tests than the general population.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are currently breastfeeding.

Fumaric acid derivatives, specifically the active metabolite monomethyl fumarate (MMF), act primarily through the activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. MMF binds to Kelch-like ECH-associated protein 1 (Keap1), which normally targets Nrf2 for degradation. By inhibiting Keap1, MMF allows Nrf2 to accumulate and translocate into the nucleus. Once in the nucleus, Nrf2 binds to the Antioxidant Response Element (ARE), upregulating the expression of cytoprotective and antioxidant genes. This reduces oxidative stress-induced damage to the myelin sheath and axons. Furthermore, it acts on the Hydroxycarboxylic acid receptor 2 (HCA2), a G protein-coupled receptor, which is thought to mediate some of its anti-inflammatory effects and the common side effect of flushing.

The pharmacodynamic effect of fumaric acid is characterized by a reduction in the inflammatory response. Clinical studies show that within the first few weeks of treatment, there is a measurable decrease in the number of circulating activated T-cells and B-cells. The duration of effect is linked to the continuous presence of the drug, as Nrf2 activation returns to baseline levels shortly after the drug is cleared from the system. Tolerance to the flushing effect often develops within a few weeks of consistent dosing, likely due to the downregulation of prostaglandin receptors.

| Parameter | Value |

|---|---|

| Bioavailability | High (exact % not defined due to rapid hydrolysis) |

| Protein Binding | 27% - 45% (Monomethyl Fumarate) |

| Half-life | ~1 hour (Monomethyl Fumarate) |

| Tmax | 2 - 5 hours (Delayed-release formulation) |

| Metabolism | Rapid hydrolysis by esterases; then TCA cycle |

| Excretion | Exhalation (60%), Renal (15.5%), Fecal (1%) |

• Molecular Formula: C4H4O4 (Fumaric Acid); C6H8O4 (Dimethyl Fumarate)
• Molecular Weight: 116.07 g/mol (Fumaric Acid); 144.13 g/mol (Dimethyl Fumarate)
• Solubility: Sparingly soluble in water; soluble in ethanol and acetone.
• Structure: A trans-butenedioic acid, consisting of a four-carbon chain with two carboxylic acid groups and a double bond between the central carbons.

Fumaric acid derivatives are classified as Nrf2 Activators and Immunomodulators. They are distinct from other MS therapies like Interferons (which are biologics) or Sphingosine 1-phosphate (S1P) receptor modulators (like fingolimod), as they primarily target the cellular antioxidant response rather than sequestering lymphocytes in lymph nodes.